A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) (NCT05462106)
A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 35 Years to 85 Years
🧪 Interventions in This Study
- Placebo (Study Part 1a) (BIOLOGICAL)
- ACI-24.060 at Dose A in Study Part 1a (BIOLOGICAL)
- ACI-24.060 at Dose B in Study Part 1a (BIOLOGICAL)
- ACI-24.060 at Dose C in Study Part 1a (BIOLOGICAL)
- ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b (BIOLOGICAL)
- Placebo (Study Part 2) (BIOLOGICAL)
- ACI-24.060 at Dose A in Study Part 2 (BIOLOGICAL)
- ACI-24.060 at Dose B in Study Part 2 (BIOLOGICAL)
- ACI-24.060 at Dose C in Study Part 2 (BIOLOGICAL)
- Placebo (Study Part 1b) (BIOLOGICAL)
- ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b (BIOLOGICAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Barrow Neurological Institute — Phoenix, Arizona
- K2 Medical Research The Villages LLC — Lady Lake, Florida
- Charter Research, LLC — Orlando, Florida
- Headlands Horizons LLC — Orlando, Florida
- Charter Research, LLC — The Villages, Florida
- Indiana University / IU Health — Indianapolis, Indiana
- University of Kansas Medical Center Research Institute — Fairway, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- The Washington University — St Louis, Missouri
- Flourish Research — Matthews, North Carolina
- Neurology Clinical, P.C. — Cordova, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- UT Health San Antonio — San Antonio, Texas
- Fundació ACE, Institut Català de Neurociències Aplicades — Barcelona,
- Hospital de la Santa Creu i Sant Pau — Barcelona,
- Hospital Universitario Virgen De Las Nieves — Granada,
- Hospital Clínico San Carlos — Madrid,
- Hospital Universitario de la Princesa — Madrid,
- Hospital Universitario Marqués de Valdecilla — Santander,
- Hospital Universitario y Politécnico La Fe — Valencia,
- Cambridge and Peterborough NHS Foundation Trust - Windsor Research Units — Cambridge,
- Liverpool University Hospitals NHS Foundation Trust — Liverpool,
- Re:Cognition Health Limited — London,
- South London and Maudsley NHS Foundation Trust of The Maudsley Hospital — London,
- Oxford Health NHS Foundation Trust — Oxford,
📞 Contact the Study Coordinator
Phone: +41 21 345 9121
Email: clinicaltrials@acimmune.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Amyloid Plaque clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.